Goldman Sachs raised its price target on TG Therapeutics, Inc. (NASDAQ:TGTX) to $39 from $37 with a Neutral rating, predicting a rise in stock price after the company disclosed 2026 revenue guidance of $875 million to $900 million. Phase 3 enrollment for BRIUMVI’s subcutaneous formulation is ahead of expectations.

TG Therapeutics, Inc. (NASDAQ:TGTX) reported Q3 2025 revenue of $161.7 million, a 93% YoY increase. U.S. BRIUMVI net sales were around $153 million, surpassing internal and Street expectations. The company emphasized financial discipline and reported GAAP net income of $390.9 million for the quarter.

TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company focusing on autoimmune diseases, particularly multiple sclerosis. Founded in 1993 and headquartered in North Carolina, it is among the top 10 long-term healthcare stocks to buy. Consider AI stocks for greater upside potential and less downside risk.

For those interested in AI stocks, consider an undervalued option that could benefit from current economic trends. Look into our report on the best short-term AI stock for potential investment opportunities. Explore more on up-and-coming streaming companies and high-growth Canadian stocks for additional investment ideas.

Read more at Yahoo Finance: Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance